Signifor clinical trials

Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor

This study looks at a medicine called Pasireotide (Signifor) for two rare cancers, Desmoplastic Small Round Cell Tumor (DSRCT) and Synovial Sarcoma. It aims to see if Pasireotide can help keep the cancer from returning after initial intense treatments, potentially improving patient outcomes.